Press |

ESMO Highlight: Ronald de Wit, Results of the CARD Trial (video)

ESMO Highlight, video.

Ronald de Wit, MD, PhD, on Prostate Cancer: Results of the CARD Trial on Cabazitaxel, Abiraterone, and Enzalutamide.

Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses study findings which showed that cabazitaxel improved radiographic progression-free survival as well as overall survival in patients with metastatic castration-resistant prostate cancer (Abstract LBA13).

READ:

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

in NEJM (The New England Journal of Medicine)

© 2019, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in